-
Mashup Score: 1Multitarget Fecal Immunochemical Test in Stool-Based Colorectal Cancer Screening - The ASCO Post - 2 month(s) ago
In a Dutch study reported in The Lancet Oncology, Wisse et al found that a multitarget fecal immunochemical test (mtFIT) improved detection of advanced adenomas vs standard FIT in colorectal cancer screening. The mtFIT used in the study measures hemoglobin, calprotectin, and serpin family F member 2. I ndividuals aged 55 to 75 years eligible for the Dutch national FIT-based colorectal cancer screening program were invited to submit both a FIT and mtFIT sample collected from the same bowel movement.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening - The ASCO Post - 2 month(s) ago
In the BLUE-C study—reported in The New England Journal of Medicine —Imperiale et al found that a next-generation multitarget stool DNA test showed high sensitivity for colorectal cancer and high specificity for advanced neoplasia compared with colonoscopy screening. The U.S. multicenter study included 20,176 participants aged ≥ 40 years who underwent colonoscopy screening, the next-generation stool DNA test, and fecal immunochemical testing (FIT). The primary outcomes were sensitivity of the next-generati
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Performance of cfDNA Blood-Based Test for Colorectal Cancer Screening - The ASCO Post - 2 month(s) ago
In the ECLIPSE study—reported in The New England Journal of Medicine —Chung et al found that a cell-free DNA (cfDNA) blood-based test had high sensitivity for colorectal cancer and high specificity for advanced neoplasia in colorectal cancer screening compared with colonoscopy. The U.S. multicenter study included 7,861 individuals eligible for colorectal cancer screening enrolled between October 2019 and September 2022 who had results for colonoscopy and cfDNA test screening. Eligible participants were
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Prevalence of Unsatisfactory Samples From FIT Tests for Colorectal Cancer Screening - The ASCO Post - 6 month(s) ago
A retrospective cohort study by Liu et al published in Cancer Epidemiology, Biomarkers & Prevention investigated the prevalence and reasons for an unsatisfactory fecal immunochemical test (FIT). Researchers found that over 10% of the tests used for routine colorectal cancer screening contained unsatisfactory samples that could not be processed, mostly due to patie nt-related reasons, including inadequate or old specimens, incomplete labeling, or a broken or leaking container. In addition, only 40.7% of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients - The ASCO Post - 6 month(s) ago
Colorectal cancer screenings are currently recommended for individuals aged 45 to 75 who have an average risk of developi ng the disease. However, many patients may not realize that the benefits of screening for this type of cancer are not always the same for older individuals. “While many [physicians] simply follow guideline recommendations for [colorectal] cancer screening in adults within this age range, this isn’t always the best approach,” explained co–lead study author Sameer Saini, MD, MS, a
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Stool-Based Colorectal Cancer Screening: Comparison of Fecal Immunochemical Tests https://t.co/Rco3f9GGwq #crcsm #colorectalcancer #screening